Chris Hemsworth Launches Personalized Wellness, Longevity Platform
Key Takeaways
- Actor Chris Hemsworth has co-founded KINSYN, a personalized wellness and longevity platform integrating physician-guided care, prescription therapies, biomarker testing, and health data.
- The platform offers skin and hair treatments, including copper peptides and topical therapies, alongside metabolic health and longevity-focused interventions.
- KINSYN uses artificial intelligence (AI) to help clinicians interpret medical records, laboratory findings, wearable data, and lifestyle information to inform individualized care.
Actor Chris Hemsworth has launched KINSYN, a personalized health and longevity platform combining physician-guided medical care, prescription therapies, biomarker testing, and AI-powered health data analysis.
Announced November 12, 2026, the platform aims to integrate medical records from participating US healthcare systems with laboratory results, wearable technology, and lifestyle information to support individualized treatment planning.
Co-founded by Hemsworth, KINSYN provides access to licensed medical professionals, prescription treatments, supplements, and ongoing health monitoring through a centralized digital platform.
KINSYN Integrates Skin and Hair Treatments With Personalized Longevity Care
KINSYN's treatment portfolio includes dermatology-related offerings such as copper peptides and topical skin and hair therapies. Additional services include metabolic health and weight management treatments involving tirzepatide and semaglutide, along with longevity-focused interventions such as nicotinamide adenine dinucleotide (NAD+), glutathione, sermorelin, and vitamin B12 injectables.
The company reports that its proprietary AI technology integrates patient health information to help clinicians develop personalized recommendations based on individual medical needs and wellness goals.
KINSYN is led medically by Jonathan Schoeff, MD, a board-certified surgeon specializing in metabolic health and personalized longevity care. Its Medical and Scientific Advisory Board includes researchers and physicians specializing in genomics, immunology, metabolic health, and precision medicine.
According to the company, prescription therapies are provided through affiliated medical practices and sourced from independent compounding pharmacies operating under Section 503A requirements. Prescriptions remain subject to clinician evaluation and medical eligibility.
The announcement did not provide clinical trial data demonstrating improved health outcomes from the integrated platform or its dermatology-related offerings.
"To me, longevity is not just about living longer. It's about how you experience your life along the way," Hemsworth said.
Source
KINSYN press release, November 12, 2026.